Recursion Pharmaceuticals, Inc. (RXRX)
- Previous Close
7.70 - Open
8.15 - Bid 7.91 x 500
- Ask 7.97 x 500
- Day's Range
7.89 - 8.27 - 52 Week Range
4.54 - 16.75 - Volume
5,782,457 - Avg. Volume
6,318,598 - Market Cap (intraday)
1.864B - Beta (5Y Monthly) 0.75
- PE Ratio (TTM)
-- - EPS (TTM)
-1.58 - Earnings Date May 6, 2024 - May 10, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
13.00
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
www.recursion.comRecent News: RXRX
Performance Overview: RXRX
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RXRX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RXRX
Valuation Measures
Market Cap
1.81B
Enterprise Value
1.47B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
36.48
Price/Book (mrq)
3.90
Enterprise Value/Revenue
33.41
Enterprise Value/EBITDA
-4.77
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-32.29%
Return on Equity (ttm)
-69.12%
Revenue (ttm)
44.58M
Net Income Avi to Common (ttm)
-328.07M
Diluted EPS (ttm)
-1.58
Balance Sheet and Cash Flow
Total Cash (mrq)
391.56M
Total Debt/Equity (mrq)
10.93%
Levered Free Cash Flow (ttm)
-187.37M